Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.55, No.3, p.229-238, 2008 |
||
Title: Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism | ||
Author: E. PAPADOPOULOU, K. ANAGNOSTOPOULOS, G. TRIPSIANIS, I. TENTES, S. KAKOLYRIS, G. GALAZIOS, E. SIVRIDIS, K. SIMOPOULOS, A. KORTSARIS | ||
Abstract: The present study was conducted to clarify the predictive and prognostic significance of serum TGF-β1 in breast cancer in relation to Ile655Val single nucleotide polymorphism (SNP) of human epidermal growth factor receptor-2 (HER-2). In a case-control study, 56 consecutive patients with primary breast cancer were prospectively included and evaluated. The control group consisted of 45 healthy women. Serum concentrations of TGF-β1 were measured by quantitative sandwich enzyme immunoassay (ELISA). HER-2 SNP was genotyped using PCR-RFLP method. Serum levels of TGF-β1 were significantly increased in breast cancer patients compared to healthy controls (pymph node metastases (p=0.009) remained the only significant independent determinant of high TGF-β1 levels. With regard to prognostic significance for advanced stages (AUC, 0.704) and lymph node metastasis (AUC, 0.683), when the optimal cut-off value was set at 65.15 pg/ml, the sensitivity was 86% and 67%, the specificity was 60% and 62% and accuracy was 66% and 64%, respectively. Survival was shorter in patients with increased serum TGF-β1 (36 months vs 46 months, p=0.022). Multivariate analysis demonstrated a marginal prognostic significance of serum TGF-β1 for survival (p=0.072). The combination of high TGF-β1 and Val-Val genotype predicts a worse prognosis than high serum TGF-β1 alone. Our findings suggest that serum TGF-β1 is involved in tumor malignancy and lymph node metastasis and could be used clinically as a useful tumor marker for evaluation, the extension and the outcome of the disease. They also provide clinical evidence for a significant association between HER-2 Ile655Val SNP and serum TGF-β1, resulting to more aggressive phenotype of the tumor and poor prognosis. |
||
Keywords: serum TGF-beta1, HER-2, polymorphism, breast cancer, survival | ||
Year: 2008, Volume: 55, Issue: 3 | Page From: 229, Page To: 238 | |
|
download file |
|